Please use this identifier to cite or link to this item:
Title: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Authors: Thura M.
Al-Aidaroos A.Q.
Gupta A. 
Chee C.E. 
Lee S.C. 
Hui K.M. 
Li J.
Guan Y.K. 
Yong W.P. 
So J. 
Chng W.J. 
Ng C.H. 
Zhou J. 
Wang L.Z. 
Yuen J.S.P. 
Ho H.S.S. 
Yi S.M.
Chiong E. 
Choo S.P. 
Ngeow J. 
Ng M.C.H. 
Chua C. 
Yeo E.S.A. 
Tan I.B.H. 
Sng J.X.E.
Tan N.Y.Z.
Thiery J.P. 
Goh B.C. 
Zeng Q. 
Issue Date: 2019
Publisher: Nature Publishing Group
Citation: Thura M., Al-Aidaroos A.Q., Gupta A., Chee C.E., Lee S.C., Hui K.M., Li J., Guan Y.K., Yong W.P., So J., Chng W.J., Ng C.H., Zhou J., Wang L.Z., Yuen J.S.P., Ho H.S.S., Yi S.M., Chiong E., Choo S.P., Ngeow J., Ng M.C.H., Chua C., Yeo E.S.A., Tan I.B.H., Sng J.X.E., Tan N.Y.Z., Thiery J.P., Goh B.C., Zeng Q. (2019). PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature Communications 10 (1). ScholarBank@NUS Repository.
Abstract: Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently expressed in several cancers. Here we show that PRL3-zumab specifically inhibits PRL3+ cancer cells in vivo, but not in vitro. PRL3 antigens are detected on the cell surface and outer exosomal membranes, implying an ‘inside-out’ externalization of PRL3. PRL3-zumab binds to surface PRL3 in a manner consistent with that in classical antibody-dependent cell-mediated cytotoxicity or antibody-dependent cellular phagocytosis tumor elimination pathways, as PRL3-zumab requires an intact Fc region and host FcγII/III receptor engagement to recruit B cells, NK cells and macrophages to PRL3+ tumor microenvironments. PRL3 is overexpressed in 80.6% of 151 fresh-frozen tumor samples across 11 common cancers examined, but not in patient-matched normal tissues, thereby implicating PRL3 as a tumor-associated antigen. Targeting externalized PRL3 antigens with PRL3-zumab may represent a feasible approach for anti-tumor immunotherapy. © 2019, The Author(s).
Source Title: Nature Communications
ISSN: 20411723
DOI: 10.1038/s41467-019-10127-x
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.pdf4.63 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.